Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 10/20 | 0.39 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.37 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.37 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.35 |
| ▸ | FUT6 | P51993 | 1/20 | 0.34 |
| ▸ | TGM2 | P21980 | 1/20 | 0.33 |
| ▸ | ESRRA | P11474 | 3/20 | 0.33 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21786901 | 0.96 | P2RY2 (0.40) | KRASP2RY2P2RY4P2RY6POLB | |
| SCHEMBL21786902 | 0.91 | JAK2 (0.43) | JAK2 | |
| SCHEMBL21786903 | 0.90 | POLG (0.35) | P2RY2P2RY4P2RY6POLBJAK2 | |
| SCHEMBL21786904 | 0.89 | POLB (0.38) | POLBJAK2ESRRA | |
| SCHEMBL21786784 | 0.86 | JAK2 (0.45) | POLBJAK2 | |
| SCHEMBL24913477 | 0.86 | ESRRA (0.34) | JAK2ESRRA | |
| SCHEMBL21787157 | 0.85 | POLG (0.38) | P2RY2P2RY4P2RY6POLBJAK2 | |
| SCHEMBL21787159 | 0.85 | POLB (0.42) | POLBJAK2 | |
| SCHEMBL24913350 | 0.84 | POLB (0.47) | KRASP2RY2P2RY4P2RY6POLB | |
| SCHEMBL21787165 | 0.84 | POLB (0.47) | KRASP2RY2P2RY4P2RY6POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200069717-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200069717-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | POLRMT, NSUN2, RNGTT | KRAS 1112/4885P2RY2 1781/4885P2RY4 1125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.